

Health care expenditure and the burden of disease due to asthma in Australia

Australian Centre for Asthma Monitoring

This publication was funded by the Australian Government Department of Health and Ageing through the National Asthma Management Program

The Australian Institute of Health and Welfare is Australia's national health and welfare statistics and information agency. The Institute's mission is *better health and wellbeing for Australians through better health and welfare statistics and information.*

Health care expenditure and the burden of disease due to asthma in Australia

Australian Centre for Asthma Monitoring
Woolcock Institute of Medical Research

July 2005

Australian Institute of Health and Welfare
Canberra

AIHW cat. no. ACM 5

© Australian Institute of Health and Welfare 2005

This work is copyright. Apart from any use as permitted under the *Copyright Act 1968*, no part may be reproduced without prior written permission from the Australian Institute of Health and Welfare. Requests and enquiries concerning reproduction and rights should be directed to the Head, Business Promotion and Media Unit, Australian Institute of Health and Welfare, GPO Box 570, Canberra ACT 2601.

A complete list of the Institute's publications is available from the Information Services and Publishing Unit, Australian Institute of Health and Welfare, GPO Box 570, Canberra ACT 2601, or via the Institute's web site at <www.aihw.gov.au>.

ISBN 1 74024 475 3

Suggested citation

Australian Centre for Asthma Monitoring 2005. Health care expenditure and the burden of disease due to asthma in Australia. AIHW cat. no. ACM 5. Canberra: AIHW.

Australian Institute of Health and Welfare

Board Chair
Hon. Peter Collins, AM, QC

Director
Dr Richard Madden

Any enquiries about or comments on this publication should be directed to:

Australian Centre for Asthma Monitoring
Woolcock Institute of Medical Research
GPO Box M77
Missenden Road
Camperdown NSW 2050
Phone: (02) 9515 5160 (International +61 2 9515 5160)
Fax: (02) 9516 1207 (International +61 2 9516 1207)
Email: acam@asthamonitoring.org

Published by Australian Institute of Health and Welfare
Printed by Pirion Printing

Contents

List of tables and figures.....	vi
Contributors	viii
Acknowledgments.....	ix
Abbreviations.....	x
Highlights	xi
1 Introduction	1
2 Methods and data sources.....	2
2.1 Health system expenditure data	2
2.2 Burden of disease data	3
2.3 Limitations of current methods.....	5
3 Health expenditure.....	8
3.1 Overall asthma expenditure	8
3.2 Asthma expenditure by health sector	11
4 Disease burden.....	20
4.1 Leading causes of disease burden in Australia.....	20
4.2 Disease burden due to asthma in Australia	21
5 Discussion and conclusions.....	24
Appendix: Statistical tables	26
Glossary.....	28
References.....	30

List of tables and figures

Table 2.1:	Some examples of disability weights from the Dutch study.....	5
Table 3.1:	Asthma expenditure per capita, 1993–94 (\$2000–01) and 2000–01, Australia.....	10
Table 4.1:	The ten leading causes of disease burden in Australia, 1996	20
Table A.1:	Asthma expenditure per capita and as a proportion of total health expenditure, by age and sex, Australia, 2000–01	26
Table A.2:	Proportions of asthma expenditure attributed to each health sector, by broad age group, Australia, 2000–01	26
Table A.3:	Change in per capita asthma expenditure by health sector and broad age group, 1993–94 and 2000–01, Australia, (2000–01 dollars)	27
Table A.4:	Per capita asthma expenditure, for hospital care, out-of-hospital medical care and pharmaceuticals, by age group and sex, Australia, 2000–01 (\$)	27
Figure 3.1:	Asthma expenditure per capita by age group and sex, Australia, 2000–01	9
Figure 3.2:	Proportion of allocated recurrent health expenditure attributed to asthma, by age group and sex, Australia, 2000–01	9
Figure 3.3:	Distribution of asthma and total allocated recurrent health expenditure among health sectors, Australia, 2000–01	11
Figure 3.4:	Proportions of asthma expenditure in each age group, by health sector, Australia, 2000–01.....	12
Figure 3.5:	Per cent change in per capita expenditure on asthma, by age group and sector, 1993–94 to 2000–01, Australia (adjusted to 2000–01 dollars).....	13
Figure 3.6:	Change in per capita expenditure on asthma, by age group and sector, 1993–94 to 2000–01, Australia (adjusted to 2000–01 dollars).....	13
Figure 3.7:	Change in per capita health expenditure, total and for asthma, by sector, 1993–94 to 2000–01 (2000–01 prices).....	14
Figure 3.8:	Asthma expenditure by health sector and age group, Australia, 2000–01	15
Figure 3.9:	Per capita expenditure for admitted and non-admitted hospital care for patients with asthma, by age group and sex, Australia, 2000–01	16
Figure 3.10:	Per capita expenditure for hospital care for patients with asthma, by age group and admission status, Australia, 2000–01.....	16
Figure 3.11:	Per capita expenditure on out-of-hospital medical care for asthma, by age group and sex, Australia, 2000–01.....	17
Figure 3.12:	Per capita expenditure on out-of-hospital medical care for asthma, by age group and type of medical care, Australia, 2000–01.....	18
Figure 3.13:	Per capita expenditure on pharmaceuticals for asthma, by age group and sex, Australia, 2000–01	18
Figure 3.14:	Per capita expenditure on pharmaceuticals for asthma, by age group and source, Australia, 2000–01	19
Figure 4.1:	Burden of disease, as years of life lost (YLL) and years of life disabled (YLD), attributable to each National Health Priority Area condition, Australia, 1996.....	21

Figure 4.2:	Burden of disease, measured as years of life lost (YLL) and years of life disabled (YLD), attributable to asthma, by age group and sex, Australia, 1996	22
Figure 4.3:	Burden of disease attributed to asthma, measured as disability-adjusted life years per 100,000 population, by age group and sex, Australia, 1996.....	22
Figure 4.4:	Comparison of years of life disabled (YLD) based on incident and prevalent asthma, by age group and sex, Australia, 1996	23

Contributors

The following staff from the Australian Centre for Asthma Monitoring (ACAM) and the Australian Institute of Health and Welfare (AIHW) were responsible for the preparation of this document:

Patricia Correll (ACAM)
John Goss (AIHW)
Guy Marks (ACAM)
Leanne Poulos (ACAM)
Margaret Williamson (ACAM)

The authors also acknowledge the contribution of Theo Vos, School of Public Health, University of Queensland, to the section on Burden of Disease.

Acknowledgments

Australian System for Monitoring Asthma

Valuable guidance was received from the members of the Management Committee of the Australian System for Monitoring Asthma during the drafting of this report. Their input is greatly appreciated.

Committee members

Professor Norbert Berend, Woolcock Institute of Medical Research

Dr Kuldeep Bhatia, Australian Institute of Health and Welfare

Professor Donald Campbell, Asthma Australia

Dr Ching Choi, Australian Institute of Health and Welfare

Professor Peter Gibson (Chair), John Hunter Hospital, Newcastle

Professor Richard Henry, Sydney Children's Hospital, Randwick (until December 2004)

Dr Christine Jenkins, National Asthma Reference Group

Mr Craig Lindsay, Department of Health and Ageing (until March 2005)

A/Prof Guy Marks, Australian Centre for Asthma Monitoring

Professor Charles Mitchell, University of Queensland

Mr David Muscatello, National Health Information Management Group

Mr Robin Ould, National Asthma Council

Professor Richard Ruffin, University of Adelaide and Queen Elizabeth Hospital

Ms Anne Taylor, National CATI Technical Reference Group (until March 2005)

Special acknowledgement

We would like to particularly acknowledge the helpful comments of Miream Steurer and Kees van Gool from the Centre for Health Economics Research and Evaluation.

Abbreviations

ACAM	Australian Centre for Asthma Monitoring
AIHW	Australian Institute of Health and Welfare
BEACH	Bettering the Evaluation And Care of Health
DALY	Disability-adjusted life year
GP	General practitioner
NHPA	National Health Priority Area
OTC	Over-the-counter
PBS	Pharmaceutical Benefits Scheme
RPBS	Repatriation Pharmaceutical Benefits Scheme
YLD	Year of life disabled
YLL	Year of life lost due to premature death

Highlights

Health care expenditure

- In the 2000–01 financial year, health expenditure on asthma was \$693 million. This was 1.4% of total health expenditure in that year.
- The proportion of total health expenditure attributed to asthma care was highest among children; particularly boys aged 5–14 years, where it was 5.5% of annual health expenditure in that age group.
- Per capita asthma expenditure was highest for children aged 0–4 years, in which, on average, \$76 was spent per boy and \$66 per girl.
- Among adults, expenditure was higher for females than males, reflecting the higher prevalence of asthma in females.
- Health expenditure on asthma increased by 21% between 1993–94 and 2000–01 (adjusted to 2000–01 dollar values). This was less than the 26% increase in overall health expenditure over the same period.
- Over half (54%) of expenditure allocated to asthma in 2000–01 was attributed to pharmaceuticals. This was substantially higher than the proportion of total health expenditure attributed to pharmaceuticals (16%).
- Asthma-related expenditure for out-of-hospital medical care (general practitioners and specialists) decreased by 16% between 1993–94 and 2000–01 in contrast to total health expenditure for out of hospital medical care, which increased by 18%.
- In each sector (hospital, out-of-hospital medical care and pharmaceutical), over 25% of expenditure for asthma was for children aged 0–14 years. In the hospital sector, 46% of expenditure for asthma was in this age group. Expenditure on out-of-hospital medical care and pharmaceuticals for people with asthma was also relatively high in the older age groups.

Burden of disease

- The Australian Burden of Disease Study estimated that asthma accounted for 64,523 disability adjusted life years (DALYs) in 1996. This figure is comprised of 8,732 years of life lost due to premature death and 55,791 years of life lost due to disability.
- Overall, asthma contributed 2.6% of all DALYs in Australia in 1996 and was the ninth leading contributor to the overall burden of disease.
- Asthma was the leading contributor to burden of disease among children aged 0–14 years, accounting for an estimated 18% of DALYs in this age group in 1996.
- Asthma contributed a similar number of years of life lived with disability as diabetes, injury and cancer. However, estimated DALYs were lower because there were fewer deaths associated with asthma.
- The estimated financial equivalent of the burden of disease due to asthma in 1996 was \$4.3 billion (2000–01 dollars).

1 Introduction

In Australia, asthma affects around 12% of the population, leading to nearly 40,000 hospitalisations (AIHW National Hospital Morbidity Dataset) and 314 deaths in 2003 (AIHW Mortality Database). Asthma was made a National Health Priority Area (NHPA) in Australia in 1999.

The purpose of this report is to provide a summary of two aspects of the economic impact of asthma in Australia: health system expenditure and the burden of disease. This information will help guide the formulation of health policy in relation to asthma.

A major portion of this report examines recent health care expenditure for asthma. The analyses presented illustrate the differentials in expenditure on asthma in various health sectors and population groups. Changes in expenditure between 1993–94 and 2000–01 are also assessed. Understanding the contribution of asthma to direct health care expenditure aids understanding of the economic impact of the disease. Furthermore, knowledge of the relative contribution of the various health care sectors (hospital, out-of-hospital medical care, and pharmaceutical) to overall asthma-related expenditure, as well as changes over time, assists in planning interventions to optimise this expenditure.

Direct health expenditure for asthma care is only one component of the costs of asthma. The economic burden of asthma extends to personal expenses incurred, such as those arising from environmental modification or alterations in domestic arrangements due to asthma (Rand & Butz 2000; Warner & Warner 1991). The impact of asthma on social and economic participation including ability to work or study, engage in social interaction and perform other expected roles also contributes to the economic burden attributable to asthma. This impact may extend to the family and/or carer of the person with asthma (Jones 2000) as well as the person themselves.

Methods to value individual components of these ‘indirect’ costs in financial terms are controversial and not universally regarded as valid (Drummond et al. 1997). The nature of these costs is such that they often do not relate exclusively to asthma, and the component attributable to asthma cannot be reliably determined. One approach to quantifying the economic impact of asthma, and other diseases, more broadly than simply by measuring direct health care expenditure, is the ‘burden of disease approach’, which has been implemented in the Global Burden of Disease Study (Murray & Lopez 1994). In this approach, the impact of disease is quantified in terms of impact on survival (‘years of life lost’) and impact on functional capacity (‘years of life disabled’). The combined effect of both of these impacts is summarised as disability-adjusted life years (DALYs), which quantify the burden attributable to a specific disease. One DALY represents one year of lost ‘good health’. It is a summary measure that reflects the overall impact of a particular disease due to morbidity and mortality. The DALY is one measure for capturing the indirect costs of specific diseases by quantifying the impact on an individual’s experience of life in less than ideal good health (Mathers et al. 1999).

The Australian Burden of Disease Study adapted the Global Burden of Disease Study techniques for the Australian context (Mathers et al. 1999). Here, we summarise the findings from that study in relation to asthma. This information has value for providing an understanding of the burden of asthma in Australia, beyond health care expenditure.

A description of the methods for deriving the health care expenditure and burden of disease data presented in this report is provided in Chapter 2.

2 Methods and data sources

2.1 Health system expenditure data

Expenditure data used in this report were obtained from the Australian Institute of Health and Welfare's National Health Expenditure Database. This report considers recurrent health expenditure that has been allocated by health sector and disease. The analyses presented do not include non-recurrent (capital) health expenditure or expenditure that is not allocated to a health sector or disease (unallocated). Therefore, in this report, references to health care expenditure always imply 'allocated recurrent' health care expenditure.

Expenditure within each age and sex group is described on a per capita basis. Per capita expenditure was calculated by dividing the total allocated recurrent expenditure on persons within an age-sex category, by the Australian resident population in that age-sex group in 2000-01. All expenditure data are in 2000-01 dollars.

The methodology used for obtaining the data contained in the National Health Expenditure Database is described in *Health System Expenditure on Disease and Injury in Australia 2000-01* (AIHW 2004). A brief summary of the methods used to derive these data for the health sectors described in this report is provided in the following sections.

2.1.1 Hospital care

Hospital care expenditure comprises expenditure for admitted and non-admitted patient care. It includes expenditure for the care administered from medical practitioners while in hospital and hospital-dispensed pharmaceuticals.

Expenditure estimates relating to admitted patients in public hospitals were obtained from those published in *Australian Hospital Statistics 2001-02* (AIHW 2003a). Expenditure relating to private hospitals was derived from the Australian Bureau of Statistics Private Health Establishments Survey.

Hospital encounters for asthma were identified as those where the principal diagnosis was asthma (International Classification of Diseases version 10 codes J45 or J46). The National Hospital Costs Data Collection was used to estimate the costs of individual episodes of acute hospitalisation for asthma based on Diagnostic Related Groups and length of stay, with adjustment for the type of hospital. Sub-acute and non-acute hospital costs were extrapolated from the sub- and non-acute patient (SNAP) study (Eagar et al. 1997) and adjusted to 2000-01 values (AIHW 2002). Health Insurance Commission data were used to estimate the cost of specialist medical services for private in-patients.

Non-admitted patients include those attending emergency departments and out-patient services. Expenditure for non-admitted patients was reported in *Australian Hospital Statistics 2001-02* (AIHW 2003a). Individual episodes were differentiated by disease based on the demographic pattern in the 1993-94 non-admitted patient disease expenditure (Mathers & Penm 1999).

2.1.2 Out-of-hospital medical care

This comprises expenditure for private medical services in the community including general practitioners (GPs) and specialists. The Bettering the Evaluation and Care of Health

(BEACH) survey data and earlier similar studies were used to allocate; expenditure on out-of-hospital medical services by disease using BEACH disease codes; expenditure for imaging and pathology; and expenditure for other medical services such as specialists based on referral patterns recorded in these data. Where there were multiple presenting problems in a GP encounter, allocation of expenditure was done on a pro rata basis. Care administered by doctors in hospitals was included in hospital care expenditure.

2.1.3 Pharmaceuticals

Expenditure on pharmaceuticals was estimated using data on prescribed as well as 'over-the-counter' (OTC) medications supplied by community pharmacies. Data on expenditure on prescription medications was obtained from the Pharmaceutical Benefits Scheme (PBS) and the Department of Veterans' Affairs Repatriation Pharmaceutical Benefits Scheme (RPBS). Data on expenditure for medications purchased on private (i.e. non-PBS/RPBS) prescriptions and for prescribed medications whose cost is below the co-payment threshold were obtained from the Pharmacy Guild Survey. The BEACH survey data were then used to allocate these expenditure data to diseases according to the GP prescribing patterns for problems managed. To estimate expenditure for specialist-written prescriptions, an assumption was made that specialist prescribing patterns were the same as GPs.

There are no data on expenditure on OTC pharmaceuticals. Total expenditure on OTC pharmaceuticals was calculated by deducting expenditure on under co-payment and private prescriptions from all non-benefit pharmaceutical expenditure, as reported in *Health Expenditure Australia 2001-02* (AIHW 2003b). Expenditure on OTC medications was allocated to specific diseases, including asthma, using information on medication use obtained in the 1989-90 ABS National Health Survey (Mathers & Penm 1999). The same data were used for allocation of OTC expenditure to disease in both the 1993-94 analysis and the 2000-01 analysis. For the latter analysis, the data were adjusted for demographic change over the interval between 1993-94 and 2000-01.

Hospital-dispensed pharmaceuticals were included in hospital care costs.

2.1.4 Other costs

Remaining expenditure for asthma were categorised as 'other costs'. This comprised expenditure for other medical services, such as allied health care provided outside of hospitals (e.g. physiotherapy) and research. Allied health expenditure was allocated to disease using the expenditure estimates from 1993-94, adjusted for demographic change. As such, these were approximations and should be interpreted with caution. Research expenditure was allocated using the Australian Bureau of Statistics research and experimental development surveys. This should also be interpreted with caution when reviewing expenditure in subgroups within the population.

2.2 Burden of disease data

Burden of disease data used in this report were obtained from the Australian Burden of Disease Study. This study reported disability-adjusted life years (DALYs) for 176 diseases, injuries and risk factors (Mathers et al. 1999).

The DALY is a summary measure of health that provides a common currency by which many different diseases, injuries and risk factors can be compared. A DALY represents a lost

year of healthy life. It is calculated by adding future years lived with disability (YLD) for incident cases of the health condition to years of life lost due to premature mortality (YLL).

$$\text{DALY} = \text{YLD} + \text{YLL}$$

In the Australian Burden of Disease Study, DALYs were then discounted using a 3% per annum time discount rate so that earlier gains in health are given a greater value than later gains (Mathers & Penm 1999). In the *Return on Investments in Public Health* report (Abelson et al. 2003) the value of a human life was estimated, on the basis of 'willingness to pay', as \$1 million. This value was derived from studies in the United States, as there are currently no available Australian studies. From this it is calculated that, on average, the financial equivalent cost of one DALY is \$60,000.

2.2.1 Years of life lost due to disability

For asthma, the largest component of the DALY is YLD. To calculate YLD for incident cases occurring in the study year, the incidence of the health condition in the study year must be ascertained. As incident cases of asthma are not routinely reported, incidence must be estimated using best available data. In the Australian Burden of Disease Study this was done using age-specific remission rates for asthma (Bronnimann & Burrows 1986), and observed death rates attributed to asthma, to extrapolate incident rates from published data on the prevalence of current asthma among school children and adults (Burrows et al. 1991; Gergen et al. 1988). Prevalent cases of current asthma were defined as those people with airway hyperresponsiveness who also reported wheeze in the preceding 12 months (Toelle et al. 1992). Incident YLD could then be calculated by multiplying the number of incident cases of disease by the duration of the disease (from year of incidence to year of remission or death) and a disability weight associated with that disease.

$$\text{YLD} = \text{incident cases} \times \text{duration of disease} \times \text{disability weight}$$

Incident YLDs are useful for estimating the potential value to be gained by preventing an incident case of a disease and, for this reason, incident YLDs were presented as the main findings of the Australian Burden of Disease Study (Mathers et al. 1999). However, prevalent YLDs can also be calculated using the prevalence of the disease in the study year multiplied by its disability weight. They reflect the burden of disability over the current year due to cases arising in preceding years (that is, prevalent cases). Prevalent YLDs are useful for indicating the burden of a disease at the time of the study. This is particularly relevant to asthma, as there are currently no effective interventions known for preventing incident cases of asthma. However, prevalent YLDs are not suitable for calculating DALY estimates, because they cannot be added to YLL. This is because YLL is inherently a component of future disease burden, while prevalent YLDs relate to current burden. For this reason, analyses of DALYs for asthma presented in this report are based on incident YLDs.

However, the Australian Burden of Disease Study also calculated prevalent YLDs and the contrasting interpretation of prevalent and incident YLDs is described in Section 2.3.2.

There are a number of methods for developing disability weights that reflect the burden of asthma relative to other conditions, injuries and risk factors. Methods for doing this usually involve valuation exercises, in which participants make judgements about where a condition lies in a continuum between perfect health and death. In the Australian Burden of Disease Study, most weights for conditions that were common in developed countries were obtained from a valuation study carried out in the Netherlands (Stouthard et al. 1997). Further weights were obtained from the Global Burden of Disease Study (World Bank 1993). Some examples of the Dutch weights are included in Stouthard et al. (1997) (see Table 2.1). In the

Australian Burden of Disease Study, the weights for asthma from the Dutch study were adjusted based on the distribution of disability due to asthma in Australia as reported in the 1998 Survey of Disability, Ageing and Carers (ABS 1999). The final weights for asthma used in the Australian Burden of Disease Study were 0.03 for mild asthma and 0.23 for severe asthma.

Table 2.1: Some examples of disability weights from the Dutch study

Weight	Disease stage, severity level or sequela
0.00–0.01	Gingivitis, dental caries
0.01–0.05	Mild asthma , mild vision loss, mild hearing loss, basal skin cancer
0.05–0.10	Low back pain, uncomplicated diabetes case, mild stable angina (NHYHA 1–2)
0.10–0.15	Mild depression, osteoarthritis (radiological grade 2) of hip or knee, epilepsy
0.15–0.20	Mild/moderate panic disorder, spina bifida (sacral), HIV seropositive
0.20–0.30	Non-invasive breast cancer or tumour <2cm (diagnostic/treatment phase), anorexia, mild/moderate obsessive–compulsive disorder
0.30–0.40	Moderate depression, multiple sclerosis in relapsing–remitting phase, severe asthma , chronic hepatitis B infection with active viral replication, deafness
0.40–0.50	Severe vision loss, medium-level spina bifida (L3–L5), osteoarthritis (Grade 3–4) operable small cell lung cancer, moderate intellectual disability (IQ 35–49)
0.50–0.65	Paraplegia, AIDS (first stage), severe chronic bronchitis or emphysema
0.65–0.80	Disseminated breast cancer, severe depression, moderately severe brain injury resulting in permanent impairments, extreme intellectual disability (IQ<20)
0.80–1.00	Severe schizophrenia, disseminated colorectal cancer, severe dementia, alcoholic psychosis, quadriplegia, stroke with multiple permanent impairments, end-stage Parkinson's disease

Source: Reproduced from Mathers et al. 1999.

2.2.2 Years of life lost due to premature mortality

The smaller component of the DALYs for asthma is the YLL. This is calculated as the difference between age of death and a defined 'normative survivorship goal', defined in the Australian Burden of Disease Study as the 1996 cohort life expectancy. Cohort life expectancy is based on a calculation that takes into account future trends in mortality. For example, in 1996 the remaining cohort life expectancy from a woman aged 50 was 34.7 years and thus YLL for a death in a 50-year-old-woman in 1996 is 34.7.

2.3 Limitations of current methods

2.3.1 Health system expenditure data

Expenditure estimates for disease are based on the attribution of allocated recurrent health expenditure using the available information about the mix of diseases and health sector utilisation. The accuracy of the expenditure estimates is limited by the accuracy of the source data on health care utilisation. In relation to asthma there are substantial problems with diagnostic misclassification (Baker et al. 2004). These problems will particularly influence the estimates of expenditure on asthma in the elderly. The substantially higher cost-weight for chronic obstructive pulmonary disease compared with asthma (National Centre for

Classification in Health 2004) is an incentive for health care providers to assign admissions to chronic obstructive pulmonary disease, rather than asthma. Often there is no certain clinical basis for distinguishing the two entities. This may lead to underestimation of hospital bed utilisation, and hence, expenditure for asthma in the elderly. There is less incentive for misclassification in the BEACH survey data but diagnostic uncertainty remains an issue.

Furthermore, in some instances, data were not available regarding how costs should be attributed. For example, there are no data relating to the patterns of prescriptions by specialists, therefore it was assumed these would be the same as for general practitioners. The validity of this assumption is untested, and hence, these data should be interpreted with some caution. Also, the data on expenditure for OTC medications for asthma was derived from a survey conducted in 1989–90. These survey data may not reflect current patterns of use of OTC medications.

2.3.2 Burden of disease data

Although the Global Burden of Disease measures have been widely accepted and taken up for monitoring health by various organisations such as the World Health Organization, there are important limitations to the method, both at a strategic level and at an implementation level (Williams 1999). The main limitation of the approach is that it includes no information on the potential effectiveness of specific interventions. Without this information the use of Burden of Disease estimates for prioritising action will be misleading. Hence, on its own it has limited value for health policy formulation.

It is important to be aware that the estimation of incident YLD, which forms the major component of DALYs for asthma, is based on expected future disability in incident cases of asthma arising during the study year. As stated above, this measure was used because it is a conceptually consistent measure of future disease burden that can be added to YLL to estimate DALYs in the given study year. Incident YLDs are relevant to assessing the potential impact of preventive interventions that would reduce the number of incident cases. They will be favourably influenced by future interventions that increase rates of remission of asthma, thereby shortening the duration of the disease. However, as we are using the incident YLD measure, the current burden of disease attributable to prevalent (that is, pre-existing) cases of asthma is not quantified in the DALY estimates presented here. Furthermore, knowledge about asthma incidence in Australia is limited because incident cases are not routinely reported. The Australian Burden of Disease Study relied on prevalence and remission data from the United States and it is uncertain whether these are reliable for estimating asthma incidence in Australia.

Prevalence-based YLDs have been calculated for all diseases and injuries, and for various categories of disease (Mathers et al. 1999). Comparison of prevalent and incident YLDs shows that the two estimates are broadly similar but prevalent YLDs are lower than incident YLDs in the youngest age group and higher than incident YLDs in the older age groups (Mathers et al. 1999). This reflects that children are generally more likely to have incident conditions while a larger proportion of the elderly population have prevalent conditions. A comparison of incident and prevalent YLDs for asthma is presented in Section 4.2.2, Figure 4.4.

There are many other uncertainties in the estimation of DALYs attributable to asthma. The calculation of incident YLD is based on estimation of both the incidence and the duration of asthma. Both of these are derived from primary data on the prevalence, age-specific mortality and remission rates. There is no universally agreed definition of prevalence of

asthma and estimates vary substantially depending on the definition that is applied (ACAM 2003; Baker et al. 2004). This matters most for young children and the elderly. The Australian Burden of Disease Study applied an epidemiological definition which has been shown to identify a population with 'asthma that matters', that is, asthma that is more likely to be persistent, to require treatment and to be associated with impact on quality of life and need for health care (Toelle et al. 1992; Toelle et al. 1997). However, some people who are labelled as having asthma, have symptoms of asthma and take treatment for asthma are not included within this definition (ACAM 2003).

3 Health expenditure

Health expenditure is a term used to describe the actual amount spent on health care services. Here, data from the Health Expenditure Database at AIHW are used to describe health expenditure for asthma in Australia. All health expenditure data reported here represent allocated, recurrent health expenditure. In 2000–01, total allocated recurrent health expenditure (government and non-government) in Australia was \$49.2 billion. In the same year, health expenditure attributable to asthma was \$693 million (1.4% of the total) (AIHW 2004).

In this report, the term ‘total health expenditure’ will be used to refer to the sum of health expenditure for all health conditions while ‘asthma expenditure’ is the component of total health expenditure that is attributed to health care for asthma.



In the following sections, asthma is compared to total health expenditure in terms of:

- (1) the rate of expenditure per capita (i.e. per person in the population);
- (2) the proportion of expenditure spent by age group or sex;
- (3) the distribution of expenditure by health sector; and
- (4) changes in expenditure between 1993–94 and 2000–01.

3.1 Overall asthma expenditure

The highest average per capita rate of asthma expenditure in the Australian population was among children (Figure 3.1). For every child aged 0–4 years, annual asthma-related expenditure was \$76 per boy and \$66 per girl. The expenditure rate was lowest among those aged 25–34 years but rose again in older people, although not as high as for children. Among adults, expenditure on asthma was generally higher for females than males. This is consistent with the higher prevalence of asthma among adult women than men (ACAM 2003).

Overall, 1.4% of allocated recurrent health expenditure was attributed to asthma. This proportion was higher among children, particularly boys aged 5–14 years, where 5.5% of health care expenditure on this age group was attributable to asthma. On the other hand, among the elderly, asthma represented a substantially lower proportion of health expenditure (0.5%) (Figure 3.2). Therefore, while per capita expenditure for asthma in the elderly is nearly as high as for children, overall, asthma represents a much smaller component of health care expenditure among the older people. This is because there are many other causes of health expenditure in the elderly.



After adjustment for inflation, there was a 21% increase in expenditure on asthma over the period 1993–94 to 2000–01 (17% for males and 27% for females) (Table 3.1). However, among children aged 0–14 years, this increase was substantially smaller and among boys aged 0–4 years, the group with highest per capita expenditure on asthma, there was actually an 11% decrease over the period, reflecting the reduction in hospitalisations for asthma among children over this period.

Table 3.1: Asthma expenditure per capita, 1993–94 (\$2000–01) and 2000–01, Australia

Sex/age group (years)	1993–94 expenditure (\$) (adjusted to \$2000–01)	2000–01 expenditure (\$)	Per cent change
Males			
0–4	85.38	76.24	–11
5–14	57.78	60.42	5
15–24	18.58	26.98	45
25–34	10.83	15.02	39
35–44	12.16	17.73	46
45–54	14.01	18.61	33
55–64	20.51	26.27	28
65–74	34.28	41.86	22
75+	35.56	48.70	37
All males	27.87	32.73	17
Females			
0–4	63.03	65.91	5
5–14	40.10	40.44	1
15–24	24.46	33.15	36
25–34	18.26	26.92	47
35–44	19.85	27.28	37
45–54	23.79	33.49	41
55–64	38.28	51.54	35
65–74	39.60	54.45	38
75+	41.38	54.77	22
All females	30.87	39.12	27
Persons			
0–4	74.49	71.21	–4
5–14	49.17	50.68	3
15–24	21.46	30.01	40
25–34	14.54	21.00	44
35–44	16.00	22.53	41
45–54	18.80	26.05	39
55–64	29.35	38.75	32
65–74	37.10	48.36	30
75+	39.19	52.40	34
All persons	29.66	35.95	21


3.2 Asthma expenditure by health sector

Health expenditure is presented here in four broad sectors:


- 1) **hospitals**, which includes inpatient, emergency and outpatient care (both public and private);
- 2) **out-of-hospital medical**, which is primarily care in the community from general practitioners as well as specialists, imaging and pathology services;
- 3) **pharmaceuticals**, including prescribed and over-the-counter medications; and
- 4) **other expenditure** which comprises aged care services, community allied health services and research.

Methods for allocating expenditure to these sectors are provided in more detail in Section 2.1.

Over half (54%) of all asthma expenditure is attributable to pharmaceuticals. This is substantially higher than the proportion of total health expenditure that is attributable to pharmaceuticals (16%) (Figure 3.3). On the other hand, a substantially lower proportion of asthma expenditure is attributable to hospital care compared with total health expenditure.





In all age groups, the highest proportion of asthma expenditure is that attributed to pharmaceuticals (Figure 3.4). Pharmaceutical expenditure comprises a greater proportion of asthma expenditure in adult age groups than for children, particularly young children, whereas children aged 0–14 years have a greater proportion of asthma expenditure in hospital care than other age groups.




Between 1993–94 and 2000–01, per capita asthma expenditure on pharmaceuticals increased in all age groups, with increases of more than \$10 per capita in the 65 years and over age group (Figures 3.5 and 3.6).


Asthma expenditure for out-of-hospital medical care (GPs and specialists) decreased in most age groups apart from a small increase among people aged 15–34 years. There was also a large proportional rise in ‘other’ expenditure on asthma recorded in the 65 years and over age group (Figure 3.5). However, as Figure 3.6 shows, this represented only a small absolute rise in the expenditure (\$3.72 per capita). This increase was almost entirely attributable to expenditure on asthma in the aged care sector.



After adjusting for inflation, per capita asthma expenditure increased in all sectors combined by 21% during the period 1993-94 to 2000-01, which was slightly less than the 26% increase in total health expenditure (Figure 3.7). The greatest difference was in the out-of-hospital medical sector, where asthma expenditure decreased by 18% while total health expenditure increased by 16%. Although the largest increase in asthma expenditure was for pharmaceuticals, the increase in pharmaceutical expenditure for asthma was less than the increase in total health expenditure on pharmaceuticals.





In each sector, over 25% of asthma expenditure was for children aged 0–14 years (Figure 3.8). In particular, nearly half (46%) of all hospital expenditure for asthma was for this age group. In the out-of-hospital medical sector, children aged 0–14 years accounted for 28% of asthma expenditure while 55% was for adults aged 15–64 years. Asthma expenditure on young children (aged 0–4 years) was least in the pharmaceutical sector, in contrast to hospital care.




Average per capita asthma expenditure for hospital care was highest for children aged 0–14 years, particularly boys. However among adults, per capita expenditure was higher in women (Figure 3.9).

As noted previously, hospital care includes both admitted and non-admitted care. For asthma, the majority of non-admitted care occurs in hospital emergency departments. Among children, asthma expenditure for those aged 0–4 years was predominantly for admitted care, while among those aged 5–14 years, a greater proportion of hospital expenditure for asthma was for non-admitted care (i.e. emergency departments) (Figure 3.10). Among people aged 65 years and over, virtually all hospital care expenditure for asthma was attributed to admitted care.





Average per capita asthma expenditure for out-of-hospital medical care, as for other sectors, was highest in young children. However, in this sector, expenditure on asthma in the elderly, particularly women, was also substantial (Figure 3.11). Comparison with data on the prevalence of asthma (ACAM 2003), which was highest in children but not particularly high in older people, suggests that there was a relatively high use of out-of-hospital medical care among older people with asthma.




Out-of-hospital medical care comprises specialist services and unreferral attendances in general practice. Among children, the highest per capita asthma expenditure was for care by general practitioners (Figure 3.12), while more per capita asthma expenditure for specialist care was attributed to people aged 55 years and over.

Asthma expenditure, per capita, on pharmaceuticals was highest in children (particularly boys) and older people (particularly women aged 55 to 84 years and men aged 65 to 84 years) (Figure 3.13). The observed high rates of pharmaceutical use in children presumably reflects the high prevalence of asthma in this age group (ACAM 2003). However, high rates of expenditure on pharmaceuticals for asthma in older people were not proportional to the observed prevalence of asthma in this age group and, therefore, might reflect relatively greater use of pharmaceuticals in older people with asthma.



Per capita expenditure attributed to prescription pharmaceuticals for asthma was highest for people aged 65 years and older, whereas expenditure on OTC pharmaceuticals for asthma was highest in 5-14-year-old children (Figure 3.14).



4 Disease burden

The Australian Burden of Disease Study quantified the impact of specified diseases in units of disability-adjusted life year or DALYs in 1996 (Mathers et al. 1999). One DALY represents one lost healthy year of life. The methods for deriving the components of DALYs have been described in Section 2.2. This section summarises the findings for asthma from that study.

4.1 Leading causes of disease burden in Australia

In Australia in 1996, there were over 2.5 million years of healthy life lost, or DALYs, due to new (incident) diseases and injuries and premature deaths occurring during that year. In the same year, there were 8,732 years of life lost (YLL) and 55,791 years of life disabled (YLD) due to asthma, which added together, total 64,523 DALYs for asthma. Asthma contributed 2.6% of all DALYs in Australia in that year and was the ninth leading contributor to the overall burden of disease. Among children aged 0–14 years, asthma contributed 18% of all DALYs, making it the leading cause of disease burden in that age group (Table 4.1).

Table 4.1: The ten leading causes of disease burden in Australia, 1996


All ages				Children aged 0–14 years			
Total DALYs in 1996		2,510,274		Total DALYs in 1996		213,369	
Rank	Disease	DALYs	Per cent of total DALYs	Rank	Disease	DALYs	Per cent of total DALYs
1	Ischaemic heart disease	311,330	12.4	1	Asthma	38,882	18.2
2	Stroke	136,578	5.4	2	Low birth weight	12,967	6.1
3	Chronic obstructive pulmonary disease	93,387	3.7	3	Attention deficit disorder	12,959	6.1
4	Depression	93,016	3.7	4	Birth trauma and asphyxia	8,113	3.8
5	Lung cancer	90,521	3.6	5	Other chromosomal abnormalities	7,516	3.5
6	Dementia	88,978	3.5	6	Congenital heart disease	7,174	3.4
7	Diabetes mellitus	74,931	3.0	7	Sudden infant death syndrome	6,550	3.1
8	Colorectal cancer	66,951	2.7	8	Depression	6,322	3.0
9	Asthma	64,523	2.6	9	Road traffic accidents	6,133	2.9
10	Osteoarthritis	56,305	2.2	10	Autism	5,897	2.8

Source: Mathers et al. 1999.

4.2 Disease burden due to asthma in Australia



4.2.1 Comparison with other National Health Priority Areas

Mortality due to asthma (YLL) is uncommon, and the major portion of DALYs due to asthma arises from disability (YLD). Years of life disabled (YLD) for asthma was similar to that in some other National Health Priority Area conditions such as diabetes and injury, cancer and arthritis/ musculoskeletal conditions (Figure 4.1). Mental health disorders contributed a far greater number of YLD than any other NHPA conditions.




4.2.2 Age and sex distribution of burden of asthma

The burden of disease attributed to new cases of asthma and deaths from asthma in 1996 was greatest among children, particularly boys (Figures 4.2 and 4.3). There were 38,882 DALYs attributed to asthma in children aged 0-14 years. However, among people aged more than 15 years, asthma burden was greater among females. These differentials reflect the higher incidence of asthma in these population groups.



As noted previously, incident YLDs indicate the future burden that would be avoided if a disease was prevented in the study year, while prevalent YLDs indicate the current burden due to existing diseases in the study year. Comparing these two measures, incident YLDs were higher in the young and lower in older age groups (Figure 4.4). This was particularly the case for males, for whom 87% of incident YLDs were attributed to persons aged less than 15 years. This reflects the substantially higher incidence of asthma in male children than in male adults.

Prevalent YLDs are useful for providing an indication of the burden of disability due to asthma in the study year because there are currently no known measures that are effective in preventing this condition. In 1996, asthma-related disability was greatest in young males aged 0–34 years, and in females the burden was greatest in those aged 15–64 years. Compared with incident YLD, a greater proportion of prevalent YLD was attributable to adults, especially females aged 15–64 years.



4.2.3 Allocating a price to the burden of asthma

The ‘burden of disease’ is a measure of the health burden specific diseases, conditions or risk factors place on society. It is informative to use this health burden estimate to calculate the economic burden of specific diseases. Techniques to ascertain the economic value that the community places on DALYs have estimated that one DALY in 1996 was worth \$60,000 to Australians (Abelson et al. 2003). Using this estimate and adjusting for inflation, the 64,523 DALYs attributed to asthma in 1996, equates financially to \$4.3 billion in 2000-01 dollars. This can be interpreted as burden, estimated in dollar units, attributable to projected disability arising from new cases of asthma and to premature mortality due to asthma, during 1996.

5 Discussion and conclusions

Overall, health care expenditure for asthma represented a rather small proportion of total allocated recurrent expenditure on health in Australia in 2000–01. Many features of the distribution of expenditure are predictable on the basis of the nature of the disease, its treatment and its known epidemiology. For example, hospitalisation rates were highest in children; hence the proportion of asthma expenditure attributable to hospital care in children was greater than in adults. The major therapeutic intervention for asthma is pharmaceutical, and this was reflected in the relatively high proportion of asthma expenditure in the pharmaceutical sector. Furthermore, the proportion of asthma expenditure attributable to pharmaceuticals was higher in adults than in children, in whom regular preventer therapy is less widely recommended and used. Finally, the observed sex differences in asthma expenditure profiles also reflect known differences in prevalence and health care utilisation: more asthma in boys than girls and more in adult women than men.

However, some aspects of the expenditure data deserve specific comment. In particular, there was a substantial inflation-adjusted rise in expenditure on asthma in all age groups except under-5 year olds and across most sectors except out-of-hospital medical care. The most noteworthy rise was in 'other' expenditure among people aged 65 years and over. However, although relatively large, it was small in absolute terms (\$3.72 per capita). Almost all of this increase occurred in the aged care sector.

The other major increase in asthma expenditure was that attributed to pharmaceuticals, particularly in the adult age range. This 7-year period saw the introduction of a number of new medications, including new formulations of inhaled corticosteroids and a combined inhaled formulation of long-acting beta agonist and corticosteroid. However, this latter formulation first became available during 2000. Although it rapidly achieved substantial market penetration (ACAM 2003), it is unlikely to have substantially influenced the asthma expenditure data for 2000–01. Perhaps more importantly this period also saw the phasing out of generic CFC-containing inhaled medications and their replacement with newly formulated preparations that were also more expensive. Finally, substantial commercial and public sector campaigns aimed at increasing the use of inhaled corticosteroids ('preventers') by people with moderate to severe asthma were undertaken during this time.

There was a reduction in asthma expenditure on out-of-hospital medical care for children during the period 1993–94 to 2000–01. There is evidence that the prevalence of diagnosed asthma and asthma symptoms among children also decreased over this time interval (Robertson et al. 2004; Toelle et al. 2004). However, it remains uncertain whether this change represents a real reduction in the prevalence of the disease and its cost burden or, alternatively, it represents a relabelling of asthma-like symptoms as a different diagnosis, with expenditure therefore attributed to another disease entity. The lack of any reduction in expenditure on pharmaceuticals for asthma in this age group lends some support to the latter explanation.

The burden of disease attributable to asthma was dominated by disabled years, especially in the youngest age group. This is consistent with the natural history of asthma: a chronic disease with highest incidence in childhood and low rates of mortality and remission. However, it is important to emphasise that these estimates of life-long burden are sensitive to the data on incidence. As noted in Section 2.3, these data are not particularly robust in relation to asthma.

The burden of disease measured by this indicator only reflects that which is borne by the individual with the disease. A missing component that is an important aspect of the burden of asthma, particularly in children, but also in the elderly, is the influence it has on the lives of family and carers (Nocon & Booth 1991). This burden may include family financial costs of asthma care and carers' loss of time for productive activity.

Asthma has economic implications for the individual as well as society. This report has summarised two aspects of the economic burden of asthma from a societal perspective: health care expenditure on asthma and burden of disease attributable to asthma-related disability and premature mortality. It highlights the importance of pharmaceutical costs as a driver of health care expenditure on asthma and the relative importance of long-term disability expectations of children with asthma as a contributor to the burden of asthma. However, at present there are few data on other aspects of the economic burden of asthma: for example, personal expenditure related to asthma and costs incurred by families and carers of people with asthma.

Appendix: Statistical tables

Table A.1: Asthma expenditure per capita and as a proportion of total health expenditure, by age and sex, Australia, 2000–01

Age group (years)	Males		Females	
	Per capita asthma expenditure \$	% of total health expenditure in this age group	Per capita asthma expenditure \$	% of total health expenditure in this age group
0 to 4	76.24	4.08	65.91	4.22
5 to 14	60.42	5.51	40.44	3.24
15 to 24	26.98	2.12	33.15	1.90
25 to 34	15.02	1.22	26.92	1.26
35 to 44	17.73	1.26	27.28	1.40
45 to 54	18.61	0.97	33.49	1.42
55 to 64	26.27	0.82	51.54	1.55
65 to 74	41.86	0.74	54.45	1.01
75 to 84	46.55	0.53	53.94	0.61
85 and over	58.05	0.35	57.02	0.34
All ages	32.73	1.45	39.12	1.37

Table A.2: Proportions of asthma expenditure attributed to each health sector, by broad age group, Australia, 2000–01

Age group (years)	Hospital (%)	Out-of-hospital medical (%)	Pharmaceutical (%)	Other (%)
0 to 4	35	15	38	12
5 to 14	33	13	50	3
15 to 34	23	16	59	2
35 to 64	21	18	57	3
65 and over	13	16	56	15
All ages	24.5	15.8	53.4	6.3%

Table A.3: Change in per capita asthma expenditure by health sector and broad age group, 1993–94 and 2000–01, Australia, (2000–01 dollars)

Age group (years)	Hospital		Out-of-hospital medical		Pharmaceutical		Other		Total expenditure	
	%change per capita	\$ change per capita	% change per capita	\$ change per capita	% change per capita	\$ change per capita	% change per capita	\$ change per capita	% change per capita	\$ change per capita
0 to 4	1	0.17	-39	-6.79	7	1.77	22	1.56	-4	-3.29
5 to 14	14	2.03	-37	-3.90	14	3.15	17	0.24	3	1.52
15 to 34	31	1.37	6	-0.22	62	5.66	28	0.11	41	7.37
35 to 64	41	1.73	-5	-0.28	61	6.03	19	0.15	38	7.63
65 and over	-9	-0.63	-14	-1.25	59	10.42	97	3.72	32	12.25
All ages	15	1.12	-18	-1.23	42	\$5.72	44	0.68	21	6.29

Table A.4: Per capita asthma expenditure, for hospital care, out-of-hospital medical care and pharmaceuticals, by age group and sex, Australia, 2000–01 (\$)

Age group (years)	Hospital			Out-of-hospital medical			Pharmaceutical		
	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
0 to 4	26.46	23.66	50.11	7.77	5.62	13.39	19.90	14.92	34.81
5 to 14	23.29	10.30	33.59	10.15	7.90	18.05	40.34	28.05	68.39
15 to 24	6.09	9.66	15.76	5.95	6.83	12.78	21.25	22.83	44.08
25 to 34	1.85	6.25	8.10	3.91	5.70	9.61	14.71	22.96	37.67
35 to 44	3.49	6.92	10.41	4.00	6.95	10.95	15.59	21.25	36.83
45 to 54	1.78	7.68	9.47	5.20	8.15	13.34	16.49	24.93	41.42
55 to 64	2.31	15.23	17.54	4.79	7.77	12.55	16.68	22.43	39.10
65 to 74	2.72	7.81	10.53	4.08	7.80	11.88	18.05	22.11	40.15
75 to 84	4.38	10.17	14.55	1.73	3.47	5.20	10.19	13.27	23.45
85 and over	7.79	9.88	17.67	0.60	1.38	1.98	1.59	2.38	3.98
All ages	7.73	9.87	8.81	5.04	6.34	5.69	18.28	20.09	19.19

Glossary

Admitted patient	A person who has been admitted to hospital for care. Compare with <i>Non-admitted patient</i> .
Airway hyperresponsiveness	Excessive twitchiness or narrowing of the airways in response to certain stimuli. This is a characteristic feature of asthma.
Asthma expenditure	The component of total health expenditure that is attributed to asthma. Compare with <i>Total health expenditure</i> .
BEACH survey	A continuous cross-sectional paper-based data collection, which collects information about the reasons for seeking medical care, the type of patients seen, the types of problems managed and treatment provided in general practice across Australia.
Disability-adjusted life years (DALY)	A DALY is equivalent to a lost year of healthy life and is used to provide a common currency by which many different diseases, injuries and risk factors can be compared. It is calculated by adding future years lived with disability (YLD) for incident cases of the health condition to years of life lost due to premature mortality (YLL) due to the condition.
Disease burden	The overall impact of a disease due to its presence in a population. This encompasses impairments to quality of life, disability and premature mortality from the disease.
Incidence	The number of new cases (of a disease, condition or event) occurring during a given period. Compare with <i>Prevalence</i> .
Non-admitted patient	A person who attends a hospital service without admission, such as those who receive care in hospital emergency departments. Compare with <i>Admitted patient</i> .
Out-of-hospital medical care	Care provided by medical doctors in the community, including general practitioners and specialists.
Over-the-counter	Medications bought from pharmacies and other dispensers in the community.
Per capita	Per person in the population.
Prescription drugs	Pharmaceutical drugs available only on the prescription of a registered medical practitioner and only from pharmacies.
Prevalence	The number or proportion of people with certain conditions in a population at a given time. Compare with <i>Incidence</i> .

Total health expenditure	The sum of health expenditure for all health conditions (i.e. allocated recurrent health expenditure). This excludes expenditure that cannot be allocated to a specific disease (e.g. ambulance services) and capital expenditure (non-recurrent).
Wheeze	Breathing difficulty accompanied by an audible whistling sound.
Years of life disabled	Years lived in less than ideal health due to a disease or health condition
Years of life lost	The difference between age of death and a defined 'normative survivorship goal', that is, the expected survival at any given age.

References

- Abelson P, Taylor R, Butler J & Gadiel D 2003. Returns on investment in public health: an epidemiological and economic analysis. Canberra: Department of Health and Ageing.
- ABS (Australian Bureau of Statistics) 1999. Disability, ageing and carers. Cat. no. 4430.0. Canberra: ABS.
- ACAM (Australian Centre for Asthma Monitoring) 2003. Asthma in Australia 2003. Asthma Series 1. AIHW cat. no. ACM 1. Available at <www.asthmamonitoring.org>. Canberra: AIHW.
- AIHW (Australian Institute of Health and Welfare) 2002. Australian health expenditure 2000–01. AIHW cat. no. HWE 20. Canberra: AIHW.
- AIHW (Australian Institute of Health and Welfare) 2003a. Australian hospital statistics 2001–02. AIHW cat. no. HSE 25. Canberra: AIHW.
- AIHW (Australian Institute of Health and Welfare) 2003b. Health expenditure Australia 2001–02. AIHW cat. no. HWE 27. Canberra: AIHW.
- AIHW (Australian Institute of Health and Welfare) 2004. Health system expenditure on disease and injury in Australia, 2000–01. AIHW cat. no. HWE 26. Canberra: AIHW.
- Baker DF, Marks GB, Poulos LM & Williamson M 2004. Review of proposed National Health Priority Area asthma indicators and data sources. AIHW cat. no. ACM 2. Available at <www.asthmamonitoring.org>. Canberra: AIHW.
- Bronnimann S & Burrows B 1986. A prospective study of the natural history of asthma. Remission and relapse rates. *Chest* 90(4):480–4.
- Burrows B, Barbee R, Cline M, Knudson R & Lebowitz M 1991. Characteristics of asthma among elderly adults in a sample of the general population. *Chest* 100(4):935–42.
- Drummond M, O'Brien B, Stoddart G & Torrance G 1997. Methods for the economic evaluation of health care programmes. New York: Oxford University Press Inc.
- Eagar K, Gordon R & Hodgkinson A et al. 1997. The Australian National Sub-acute and Non-acute Patient (AN-SNAP) casemix classification study. Wollongong: Centre for Health Service Development, University of Wollongong.
- Gergen P, Mullally D & Evans R 1988. National survey of prevalence of asthma among children in the United States 1976 to 1980. *Pediatrics* 81(1):1–7.
- Jones PW 2000. The social impact of asthma in children. In: Weiss KB, Buist AS & Sullivan SD (eds). Lung biology in health and disease: asthma's impact on society – the social and economic burden. New York: Marcel Dekker.

- Mathers C & Penm R 1999. Health system costs of injury, poisoning and musculoskeletal disorders in Australia 1993-94. AIHW cat. no. HWE 12. Canberra: AIHW.
- Mathers C, Vos T & Stevenson C 1999. The burden of disease and injury in Australia. AIHW cat. no. PHE 17. Canberra: AIHW.
- Murray CJ & Lopez AD 1994. Quantifying disability: data, methods and results. *Bulletin of the World Health Organization* 72(3):481-94.
- National Centre for Classification in Health 2004. Australian refined diagnosis related groups version 5.1. Canberra: Australian Department of Health and Ageing.
- Nocon A & Booth T 1991. The social impact of asthma. *Family Practice* 8:37-41.
- Rand CS & Butz AM 2000. Psycho-social factors in chronic asthma. In: Weiss KB, Buist AS & Sullivan SD (eds). *Lung biology in health and disease: asthma's impact on society – the social and economic burden*. New York: Marcel Dekker, 181-217.
- Robertson CF, Roberts MF & Kappers JH 2004. Asthma prevalence in Melbourne schoolchildren: have we reached the peak? *Medical Journal of Australia* 180(6):273-6.
- Stouthard MEA, Essink-Bot M, Bonsel GM, Garendregy JJ, Kramer PGN, van de Water HPA et al. 1997. Disability weights for diseases in the Netherlands. Rotterdam: Department of Public Health, Erasmus University.
- Toelle BG, Ng K, Belousova E, Salome CM, Peat JK & Marks GB 2004. Prevalence of asthma and allergy in schoolchildren in Belmont, Australia: three cross sectional surveys over 20 years. *BMJ* 328(7436):386-7.
- Toelle BG, Peat JK, Salome CM, Mellis CM & Woolcock AJ 1992. Toward a definition of asthma for epidemiology. *American Review of Respiratory Disease* 146:633-7.
- Toelle BG, Peat JK, van den Berg R, Dermand J & Woolcock A 1997. Comparison of three definitions of asthma: a longitudinal perspective. *Journal of Asthma* 34:161-7.
- Warner JA & Warner JO 1991. Allergen avoidance in childhood asthma. *Respiratory Medicine* 85:101-5.
- Williams A 1999. Calculating the global burden of disease: time for a strategic reappraisal? *Health Economics* 8:1-8.
- World Bank 1993. *World Development Report 1993: investing in health*. New York: Oxford University Press.